

1 **Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies**
2 **to SARS-CoV-2**

3 Douglas F. Lake^{1*#}, Alexa J. Roeder^{1*}, Erin Kaleta², Paniz Jasbi³, Kirsten Pfeffer¹,
4 Calvin Koelbel¹ Sivakumar Periasamy^{4,5} Natalia Kuzmina^{4,5} Alexander Bukreyev^{4,5,6},
5 Thomas E. Grys², Liang Wu⁷, John R Mills⁷, Kathrine McAulay², Maria Gonzalez-Moa⁸,
6 Alim Seit-Nebi⁸, and Sergei Svarovsky⁸

7
8 Affiliations:

- 9 1. School of Life Sciences, Arizona State University, Tempe AZ, USA
10 2. Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology,
11 Scottsdale, AZ, USA
12 3. College of Health Solutions, Arizona State University, Phoenix AZ, USA
13 4. Department of Pathology, University of Texas Medical Branch at Galveston,
14 Galveston, TX USA
15 5. Galveston National Laboratory, University of Texas Medical Branch at Galveston,
16 Galveston, TX USA
17 6. Department of Microbiology and Immunology University of Texas Medical Branch
18 at Galveston, Galveston, TX USA
19 7. Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology,
20 Rochester, MN USA
21 8. Axim Biotechnologies Inc, San Diego, CA USA

22 *Co-first authors

23
24 #Address correspondence to Douglas F. Lake, douglas.lake@asu.edu

25
26 Word Count: 2498

27

28 **Abstract:**

29 **Background:** After receiving a COVID-19 vaccine, most recipients want to know if they
30 are protected from infection and for how long. Since neutralizing antibodies are a
31 correlate of protection, we developed a lateral flow assay (LFA) that measures levels of
32 neutralizing antibodies from a drop of blood. The LFA is based on the principle that
33 neutralizing antibodies block binding of the receptor-binding domain (RBD) to
34 angiotensin-converting enzyme 2 (ACE2).

35 **Methods:** The ability of the LFA was assessed to correctly measure neutralization of
36 sera, plasma or whole blood from patients with COVID-19 using SARS-CoV-2
37 microneutralization assays. We also determined if the LFA distinguished patients with
38 seasonal respiratory viruses from patients with COVID-19. To demonstrate the
39 usefulness of the LFA, we tested previously infected and non-infected COVID-19
40 vaccine recipients at baseline and after first and second vaccine doses.

41 **Results:** The LFA compared favorably with SARS-CoV-2 microneutralization assays
42 with an area under the ROC curve of 98%. Sera obtained from patients with seasonal
43 coronaviruses did not show neutralizing activity in the LFA. After a single mRNA
44 vaccine dose, 87% of previously infected individuals demonstrated high levels of
45 neutralizing antibodies. However, if individuals were not previously infected only 24%
46 demonstrated high levels of neutralizing antibodies after one vaccine dose. A second
47 dose boosted neutralizing antibody levels just 8% higher in previously infected
48 individuals, but over 63% higher in non-infected individuals.

49 **Conclusions:** A rapid, semi-quantitative, highly portable and inexpensive neutralizing
50 antibody test might be useful for monitoring rise and fall in vaccine-induced neutralizing
51 antibodies to COVID-19.

52

53 **KEYWORDS**

54 Neutralizing Antibodies, COVID-19, SARS-CoV-2, Lateral Flow Assay, RBD, ACE2

55 INTRODUCTION

56 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes
57 COVID-19 and originated in Wuhan, China in December 2019 [1–3]. Vaccines continue
58 to be tested [4,5] with the goal of preventing COVID-19 via induction of neutralizing
59 antibodies (NAbs) and anti-viral T cells. Vaccine trials show that RNA vaccines elicit
60 protective immunity, but durability of natural and vaccine-induced immunity is not fully
61 known [5]. Several groups reported that up to one-third of serum samples from
62 individuals who recovered from COVID-19 do not neutralize SARS-CoV-2 [6–8].
63 Whether previously infected or vaccinated, it is informative for individuals to learn if they
64 generated high levels of NAbs so that they can resume normal activities without fear of
65 re-infection and transmitting the virus [9–11].

66 Viral neutralization assays measure antibodies that block infection of host cells.
67 The gold standard of neutralization for SARS-CoV-2 measures reduction of viral
68 plaques or foci in microneutralization assays. These assays are slow, laborious, require
69 highly trained personnel and a BSL3 facility. Another challenge is that neutralization
70 assays require careful titration of virus and depend on host cells for infection, both of
71 which add variability to the assay. These limitations prevent use of SARS-CoV-2
72 neutralization assays for clinical applications.

73 SARS-CoV-2 uses receptor binding domain (RBD) on spike protein to bind
74 angiotensin converting enzyme 2 (ACE2) on host cells; RBD appears to be the principal
75 neutralizing domain [12,13]. Using this knowledge, we developed a lateral flow assay
76 (LFA) that measures levels of NAbs which block RBD from binding to ACE2. Other
77 groups have developed RBD-ACE2-based competition ELISAs[18,19] but none have

78 developed a rapid, highly portable, semi-quantitative test that can easily be incorporated
79 into clinical settings or research studies where traditional laboratory or neutralization
80 tests are not practical.

81

82 MATERIALS AND METHODS

83 *Human Subjects and Samples*

84 Serum and finger-stick blood samples were collected for this study under an
85 Arizona State University institutional review board (IRB)-approved protocol
86 #0601000548 and Mayo Clinic IRB protocol #20-004544. Serum samples obtained
87 from excess clinical samples at Mayo Clinic were left over from normal workflow.
88 COVID-19 samples ranged from 3 to 84 days post PCR positive result.

89 Twenty-seven control serum samples from patients with non-COVID-19
90 respiratory illnesses as determined by the FilmArray Respiratory Panel 2 (Biofire
91 Diagnostics) were collected from patients from 2/14/17 – 4/6/20 as part of routine
92 clinical workflow. All residual clinical samples were stored at 2-8°C for up to 7 days, and
93 frozen at -80°C thereafter.

94

95 *SARS-CoV-2 Microneutralization Assay*

96 A microneutralization assay was performed using a recombinant SARS-CoV-2
97 expressing mNeonGreen (SARS-CoV-2ng) as previously described [16]. Inhibitory
98 concentrations for which 50% of virus is neutralized by serum antibodies (IC₅₀ values)
99 were obtained on a set of 38 COVID-19 sera. Sixty µl aliquots of SARS-CoV-2ng were
100 pre-incubated for 1 h in 5% CO₂ at 37°C with 60µl 2-fold serum dilutions in cell culture

101 media, and 100 μ l were inoculated onto Vero-E6 monolayers in black polystyrene 96-
102 well plates with clear bottoms (Corning) in duplicate. The final amount of the virus was
103 200 PFU/well, the starting serum dilution was 1:20 and the end dilution was 1:1280
104 unless an IC₅₀ was not reached in which case serum was diluted to 1:10240. Cells were
105 maintained in Minimal Essential Medium (ThermoFisher Scientific) supplemented by 2%
106 FBS (HyClone) and 0.1% gentamycin in 5% CO₂ at 37°C. After 2 days of incubation,
107 fluorescence intensity of infected cells was measured at 488 nm using a Synergy 2 Cell
108 Imaging Reader (Biotek). Signal was normalized to virus alone with no serum added
109 and reported as percent neutralization. IC₅₀ was calculated with GraphPad Prism 6.0
110 software. Work was performed in a BSL-3 biocontainment laboratory of the University of
111 Texas Medical Branch, Galveston, TX.

112

113 *Serologic Antibody Assay*

114 The Ortho Vitros Anti-SARS-CoV-2 IgG test (Ortho Vitros test) was performed on
115 an Ortho Clinical Diagnostics Vitros 3600 Immunodiagnosics System at the Mayo Clinic.
116 This assay is approved for clinical testing under FDA Emergency Use Authorization to
117 qualitatively detect antibody to the S1 subunit of SARS-CoV-2 spike protein. Results are
118 reported as reactive (S/CO \geq 1.0) or nonreactive (S/CO $<$ 1.0). Specimens were tested
119 within 7 days of collection and stored at 2-8°C. The same 38 serum samples were run
120 in the Ortho Vitros test, microneutralization assay, and the LFA.

121

122

123 *Lateral Flow Neutralizing Antibody Assay*

124 The Lateral Flow NAb assay was developed to measure levels of antibodies that
125 compete with ACE2 for binding to RBD. The LFA single port cassette (Empowered
126 Diagnostics) contains a test strip composed of a sample pad, blood filter, conjugate pad,
127 nitrocellulose membrane striped with test and control lines, and an absorbent pad (Axim
128 Biotechnologies Inc). The LFA also contains a control mouse antibody conjugated to
129 red gold nanospheres and corresponding anti-mouse IgG striped at the control line.

130 LFAs were run at room temperature on a flat surface for 10 minutes prior to
131 reading results. To perform the test, 6.7µl of serum or 10ul whole blood were added to
132 the sample port followed by 60µl of chase buffer. After 10 minutes, densities of both test
133 and control lines were recorded in an iDetekt RDS-2500 density reader.

134 The test leverages the interaction between RBD-conjugated green-gold
135 nanoshells (Nanocomposix) that bind ACE2 at the test line when RBD-neutralizing
136 antibodies (RBD-NAbs) are absent or low. Test line density is inversely proportional to
137 RBD-NAbs present within the sample. As a semi-quantitative test, the results of the LFA
138 can be interpreted using a scorecard or a densitometer. A red line across from the “C”
139 indicates that the test ran properly. An absent or faint test line indicates high levels of
140 RBD-NAbs, whereas a dark test line suggests low or lack of RBD-NAbs.

141
142 Precision testing was performed using sera from one highly, and one non-
143 neutralizing donor in replicates of 10. Density values were recorded as above
144 and %CVs calculated using the formula: $(\text{Standard Deviation}/\text{Mean}) * 100\%$.

145



146 *Data Analysis*

147 Pearson's correlation (r) was conducted to assess the strength and significance
148 of associations between the LFA, the Ortho Vitros test and IC_{50} values. Regression
149 analysis using IC_{50} values evaluated consistency [14] while Bland-Altman plots
150 assessed agreement and bias [17,18]. Correlation analysis was conducted using IBM
151 SPSS. For two-group analysis, IC_{50} values corresponding to >240 were categorized as
152 titer of $\geq 1:320$ (neutralizing), whereas IC_{50} values ≤ 240 were categorized as $\leq 1:160$
153 (low/non-neutralizing). Receiver operating characteristic (ROC) analysis was performed
154 to assess accuracy, sensitivity, and specificity of the LFA and Ortho Vitros tests in
155 assessing neutralization; optimal cutoffs for each method were established to maximize
156 area under curve (AUC) [19,20]. ROC analysis was conducted using R language in the
157 RStudio environment (version 3.6.2; RStudio PBC). All analyses were conducted using
158 raw values; data were not normalized, transformed, or scaled.

159

160 RESULTS

161 As shown at the bottom in **Figure 1A**, serum containing high levels of NAbs
162 results in a weak or ghost test line because NAbs bind RBD on green-gold beads,
163 preventing RBD from binding to the ACE2 receptor at the test line. Serum with low
164 levels of NAbs results in a strong test line because little to no antibodies prevent RBD
165 on beads from binding to ACE2. **Figure 1B** demonstrates results of the test using
166 COVID-19 sera with different levels of NAbs.




167

168 **Figure 1. (A)** Schematic of Neutralization LFA. Below each graphic is a representative
 169 image of a lateral flow strip demonstrating actual line density. Addition of non-
 170 COVID19-immune serum or plasma (*top*) does not block binding of RBD-beads (green
 171 particles) to ACE2 resulting in the RBD-bead–ACE2 complex creating a visible line.

172 Addition of patient serum with moderate titer NABs to the sample pad creates a weak
173 line (*middle*). Addition of patient serum with high titer NABs ($> 1:640$) blocks binding of
174 RBD-beads to ACE2 such that no line is observed at the test location on the strip
175 (*bottom*). Red control line represents capture of a mouse monoclonal antibody coupled
176 to red beads. **(B)** Scorecard for measuring levels of NABs. Red control line across from
177 the “C” on the cassette indicates that the test ran properly and the green test line across
178 from the “T” can be used to measure the ability of plasma or serum to block RBD on
179 gold nanoshells from binding to ACE2. **(0)** represents patient serum producing a visually
180 non-existent line with density units of 10,095 and an $IC_{50}>500$ ($IC_{50}=1151$); **(1)**
181 represents patient serum with a line density of 132,503 and an IC_{50} of 396; **(2)**
182 represents patient serum with a line density of 317,156 and an IC_{50} of 243; **(3)**
183 represents patient serum with a line density of 645,040 and an IC_{50} of 96.
184

185 To support the application of the LFA to measure NAb levels to SARS-CoV-2, we
186 tested 38 serum samples that were assigned IC_{50} values in a SARS-CoV-2
187 microneutralization assay [16]. The experiment was performed in a blinded manner
188 such that personnel running either the LFA or the microneutralization assay did not
189 know the results of the comparator test. When line densities from the LFA were plotted
190 against IC_{50} values determined in the microneutralization assay, serum samples with
191 strong neutralization activity demonstrated low line densities; this indicates that NABs
192 inhibited RBD from binding to ACE2 (**Figure 2**).



193

194 **Figure 2.** Comparison of RBD-ACE2 competition LFA density values with IC₅₀ values
195 determined in a SARS-CoV-2 microneutralization assay on 38 samples (collected 3 to
196 90 days after PCR positive result). Ranges of IC₅₀ values are shown on the X-axis
197 plotted against LFA line density units on the Y-axis.

198

199


200 Next, we determined if the LFA detected neutralization activity in serum samples

201 collected from patients with other PCR-confirmed respiratory viruses including seasonal

202 coronaviruses (**Figure 3A**) and for serum samples collected prior to December 2019

203 (**Figure 3B**). Neither seasonal respiratory virus sera, nor pre-December 2019 samples

204 showed neutralizing activity.



205


206 **Figure 3. A)** Serum samples collected with PCR-confirmed diagnosis of seasonal
207 respiratory viruses (Coronavirus OC43, blue; Coronavirus HKU-1, green; Coronavirus
208 NL-63, pink; influenza A, orange, influenza B, red ; parainfluenza, purple ; rhinovirus,
209 teal ; respiratory syncycial virus, yellow ; and adenovirus, black were run on the LFA as
210 described in Methods. A positive control serum from a convalescent COVID-19 patient
211 is shown on the far right of the bar graph in white. **B)** Serum samples collected pre-
212 December 2019. Cutoff value of 263,000 density units was calculated based on
213 receiver operating characteristic curves (see Figure 6).

214

215 We then compared both the Ortho Vitros test and our LFA to sera with IC₅₀
216 values determined in the SARS-CoV-2 microneutralization assay using 38 COVID-19
217 sera. To assess agreement between our LFA and the Ortho Vitros test, density units
218 from the LFA and values from the Ortho test were regressed onto IC₅₀ values
219 (Supplemental Figure S1).

220

221



222 **Supplemental Figure S1.** Regression analysis between (A) Ortho Vitros SARS-CoV-2
223 IgG test and (B) LFA and titer. Regression plots show explained variance (R^2) between
224 compared methods. Thirty-eight samples were tested.


225

226

227 LFA values accounted for roughly 52% of observed variance in IC₅₀ values, while
228 the Ortho Vitros test accounted for approximately 27% of IC₅₀ variance. LFA showed
229 significant negative correlation with IC₅₀ values ($r = -0.720$, $p < 0.001$), while the Ortho
230 Vitros test values showed a significant positive correlation to IC₅₀ values ($r = 0.522$, $p =$
231 0.001). Additionally, the LFA and Ortho Vitros test values correlated with each other ($r =$
232 -0.572 , $p < 0.001$).

233 To evaluate bias, mean differences and 95% confidence intervals (CIs) were
234 calculated and plotted alongside limits of agreement (Figure 4). Both LFA and Ortho

235 Vitros test values showed strong agreement with titer, although the Ortho Vitros test
236 showed a tendency to underestimate neutralizing capacity while the LFA method
237 showed no bias.
238



239
240 **Figure 4.** Bland-Altman plots showing bias (mean difference and 95% CI) and
241 computed limits of agreement (mean difference \pm 2SD) between **(A)** Ortho Vitros Anti-
242 SARS-CoV-2 IgG test and IC₅₀ values and **(B)** our LFA and IC₅₀ values. Thirty-eight
243 samples were tested.


244
245
246 ROC analysis was performed to assess the ability of the LFA and the Ortho
247 Vitros test to classify low/non-neutralizing (Neg, <1:160), and highly neutralizing groups
248 (\geq 1:320) (**Figure 5**). As shown in **Figure 5B** and **5D**, the LFA misclassified one non-
249 neutralizing sample (Neg, <1:160) as neutralizing (\geq 1:320) which the Ortho Vitros test
250 also misclassified as neutralizing. The Ortho test also incorrectly classified five
251 additional neutralizing samples as non-neutralizing.

252 Our LFA showed high accuracy for classification of neutralizing samples (AUC =
253 0.978), while the Ortho Vitros test showed modest accuracy (AUC = 0.856). Notably,
254 while both methods showed roughly 90% sensitivity, the Ortho Vitros test showed only

255 70% specificity. In contrast, the LFA showed perfect specificity (100%) in this analysis of
256 38 samples.

257 Optimal cutoffs were computed to maximize AUC. For the LFA, density unit
258 values below 263,000 classify samples as neutralizing and correspond to titers $\geq 1:320$.
259 Density values above this LFA cutoff classify samples in the non-neutralizing group. For
260 the Ortho Vitros test, values between 0 and 23.3 were representative of non-neutralizing
261 capacity, whereas values above 23.3 were reflective of the neutralizing group.

262



263 **Figure 5. (A)** Univariate ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG test for
 264 discrimination of neutralizing samples ($\geq 1:320$) [AUC: 0.856, 95% CI: 0.697—0.953,
 265 sensitivity = 0.9, specificity = 0.7]. **(B)** Box plot of Ortho Vitros Anti-SARS-CoV-2 IgG
 266 test values between neutralizing ($\geq 1:320$) and non-neutralizing (Neg—1:160) groups. **(C)**
 267 Univariate ROC analysis of LFA for discrimination of neutralizing samples ($\geq 1:320$)
 268 [AUC: 0.978, 95% CI: 0.908—1.0, sensitivity = 0.9, specificity = 1.0]. **(D)** Box plot of LFA
 269 values between neutralizing ($\geq 1:320$) and non-neutralizing (Neg—1:160) groups.

270
 271 Precision studies were performed on replicate samples (n=10) and showed a CV
 272 of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum
 273 sample from the low neutralizing range (Supplemental Table 1).

274

Low Neutralizing Range			
10 min	C	T	T/C Ratio at 10 min
1	503764	932173	1.850416068
2	484316	944154	1.949458618
3	509424	902070	1.770764628
4	441318	840951	1.905544301
5	484558	990076	2.043255916
6	472319	906922	1.920147189
7	519936	971429	1.868362645
8	495254	992223	2.00346287
9	467545	816303	1.745934616
10	534262	941643	1.762511652
Average	491269.6	923794.4	1.88198585
STD Dev	25849.98843	55966.17114	0.096780674
%CV	5.26	6.06	5.14

275

High Neutralizing Range			
10 min	C	T	T/C Ratio at 10 min
1	415421	232022	0.558522559
2	404845	286183	0.706895232
3	419873	261146	0.621964261
4	417475	248141	0.594385293
5	409970	263808	0.64348123
6	397812	294120	0.739344213
7	409681	237096	0.578733209
8	412275	242082	0.587185738
9	373751	222959	0.596544223
10	373339	224335	0.600888201
Average	403444.2	251189.2	0.622794416
STD Dev	16097.74032	23457.01668	0.055137744
%CV	3.99	9.34	8.85


276 **Supplemental Table 1.** Precision study using one Low Neutralizing Range serum
 277 sample and one High Neutralizing Range serum sample in replicates of ten. Low range
 278 neutralization is defined as densities from 370,000 – 800,000. The used for precision
 279 analysis was from an individual who recovered from COVID-19 but did not neutralize
 280 virus in the microneutralization assay ($IC_{50} < 20$). High neutralization range samples are
 281 defined as densities from 10,000 – 369,999. This sample has an IC_{50} of 248.

282

283 Precision studies were performed on replicate samples (n=10) and showed a CV
 284 of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum
 285 sample from the low neutralizing range (**Supplemental Table 1**).

286
287

Since NAb levels may be considered correlates of protection, we tested sera from RNA vaccine recipients (mRNA-1723 and BNT162b2) in “previously infected” and “not previously infected” individuals using finger-stick blood in the rapid LFA (**Figure 6**). In *previously infected* individuals at baseline (within 3 months of PCR-based diagnosis), 38% demonstrated high levels of NABs. After the first vaccine dose, 87% of *previously infected* individuals demonstrated high NAb levels, while only 24% of *not previously infected* individuals developed high levels of NABs. After the second vaccine dose, levels of NABs increased to 95% in the *previously infected* cohort, while NAb levels increased to 87% in the *not previously infected* cohort. This data suggests that a second vaccine dose is important for highest levels of NABs.



297

298

299 **Figure 6. NAb levels in prior infection and vaccine-induced individuals. (A)**
300 Baseline indicates within one week of first vaccine dose; Post-1st Dose indicates within
301 one week of 2nd vaccine dose; Post 2nd Dose indicates 10-20 days after 2nd vaccine
302 dose. High and Low indicates density ranges of Test lines shown in (B). Densities were
303 read in a reader as described in Methods. Serum titers that correspond to high range
304 densities are >1:1280 to ≥1:160. Serum titers corresponding to low range densities are
305 <1:160.

306

307 DISCUSSION

308 We developed a rapid test that measures levels of NAbs in serum and whole
309 blood. As shown in **Figure 2**, the LFA correlates well with serologic titers determined
310 using a SARS-CoV-2 microneutralization assay, especially when serum sample IC₅₀
311 values are >250. Advantages of the LFA test are that it can be inexpensively and
312 rapidly deployed to determine levels of NAbs in vaccine recipients. Moreover, the test
313 can be used longitudinally to evaluate duration of protective immunity in naturally
314 infected and vaccinated individuals—many more than could ever be evaluated using
315 BSL2 or BSL3-based neutralization assays.

316

317 The LFA and Ortho Vitros test showed a significant correlation with each other (r
318 = -0.572, $p < 0.001$), displaying good linear relation ($r = -0.720$, $p < 0.001$)[21]. The LFA
319 accounts for 52% of observed IC₅₀ variance ($R^2 = 0.5187$), while the Ortho Vitros test
320 accounts for 27% ($R^2 = 0.2725$). Although absolute quantitation demands an excellent
321 coefficient of determination ($R^2 \geq 0.99$)[22], variables with $R^2 \geq 0.5$ are highly predictive
322 in univariate regression models while measures with $R^2 < 0.5$ are recommended for use
323 in multivariate models with complementary measures to increase predictive accuracy

324 [23,24]. Bland-Altman analysis (**Figure 4**) showed the Ortho Vitros test to be prone to
325 underestimation of IC₅₀ values, while the LFA method did not exhibit over- or
326 underestimation bias. Furthermore, across mean values for both methods, the LFA
327 showed discrete differential values while the Ortho Vitros test struggled to differentiate
328 high neutralizing samples.

329

330 Using our rapid test to measure NABs in previously infected vaccine recipients
331 and those who were not infected agrees with other studies in BSL3 facilities using
332 serum from venipuncture blood [5,25–29]. Natural infection may not elicit high levels of
333 NABs [6–8], but a first dose of vaccine induces high levels of NABs in the majority of
334 recipients similar to 2 doses of vaccine in non-previously infected individuals,
335 suggesting natural infection primes the immune system[30]. In naïve individuals, a
336 single dose of vaccine elicits high NAb levels (Titers >1:160) in only 24% of vaccine
337 recipients, leaving 76% of vaccine recipients with titers lower than 1:160 which would
338 not qualify for convalescent plasma donation according to FDA memo of March 9,2021.
339 After a second vaccine dose, the LFA indicated high levels of NABs in 87% of recipients,
340 identical to levels observed in previously infected individuals after the first vaccine dose.
341 These findings might suggest that a booster (3rd vaccine dose) in non-infected
342 individuals could induce the highest levels of NABs in the most people.

343

344 Limitations of the LFA are that it uses only the RBD portion of spike protein.
345 Although the vast majority of reports indicate that the principle neutralizing domain is the
346 RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by

347 binding to the N-terminal domain of spike protein [31,32]. Also, since the spike protein
348 assumes multiple conformations during viral binding and entry [33], neutralizing
349 epitopes exist on the quaternary structure of spike [32]. Although RBDs on the
350 nanoparticles may associate, it is not known if they assume a native conformation.

351 Other limitations are the binary nature of this data analysis (high and low
352 neutralizing) of a continuous assay. NAb levels should be evaluated longitudinally to
353 assess rise and fall in NAb levels; this rapid test is well-suited for that role. Another
354 limitation is that the LFA does not differentiate high affinity anti-RBD NAb from an
355 abundance of lower affinity anti-RBD NAb.

356 This test may prove useful in monitoring COVID-19 vaccine recipients as a
357 correlate of protection. It would be logistically difficult to obtain a tube of blood from
358 every vaccine recipient for BSL3 work. However, since this LFA requires only a drop of
359 blood, individual use of this test might lead to more comprehensive longitudinal
360 monitoring of protective humoral immunity and indicate when boosters might be
361 required.

362
363

364 AUTHOR CONTRIBUTIONS

365 DL, SS and AS-N developed the LFA. AJ performed the experiments and interpreted
366 the results. PJ performed statistical analysis. EK, TG and KM contributed samples.
367 CK, AJ and KP tested vaccine recipients and interpreted results. SP, NK and AB
368 performed SARS-CoV-2 microneutralization assays and interpreted results LW and JM
369 contributed samples for preliminary experiments. MM-G designed the strip layout and
370 produced the strips for the vaccine study.

371

372 CONFLICTS OF INTEREST STATEMENT

373 DL and SS are co-founders of Sapphire, the research division of Axim Biotech. SS, MM-
374 G and AS-N are employees of Axim Biotech. Other authors have no conflicts regarding
375 this work.

376

377 FUNDING

378 This study was funded in part by Axim Biotech, San Diego, CA

379

380 References

- 381 [1] I. Ghinai, T.D. McPherson, J.C. Hunter, H.L. Kirking, D. Christiansen, K. Joshi, R. Rubin, S.
382 Morales-Estrada, S.R. Black, M. Pacilli, M.J. Fricchione, R.K. Chugh, K.A. Walblay, N.S.
383 Ahmed, W.C. Stoecker, N.F. Hasan, D.P. Burdsall, H.E. Reese, M. Wallace, C. Wang, D.
384 Moeller, J. Korpics, S.A. Novosad, I. Benowitz, M.W. Jacobs, V.S. Dasari, M.T. Patel, J.
385 Kauerauf, E.M. Charles, N.O. Ezike, V. Chu, C.M. Midgley, M.A. Rolfes, S.I. Gerber, X. Lu, S.
386 Lindstrom, J.R. Verani, J.E. Layden, S. Brister, K. Goldesberry, S. Hoferka, D. Jovanov, D.
387 Nims, L. Saathoff-Huber, C. Hoskin Snelling, H. Adil, R. Ali, E. Andreychak, K. Bemis, M. Frias,
388 P. Quartey-Kumapley, K. Baskerville, E. Murphy, E. Murskyj, Z. Noffsinger, J. Vercillo, A.
389 Elliott, U.S. Onwuta, D. Burck, G. Abedi, R.M. Burke, R. Fagan, J. Farrar, A.M. Fry, A.J. Hall,
390 A. Haynes, C. Hoff, S. Kamili, M.E. Killerby, L. Kim, S.A. Kujawski, D.T. Kuhar, B. Lynch, L.
391 Malapati, M. Marlow, J.R. Murray, B. Rha, S.K.K. Sakthivel, S.E. Smith-Jeffcoat, E. Soda, L.
392 Wang, B.L. Whitaker, T.M. Uyeki, First known person-to-person transmission of severe
393 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA, *The Lancet*. 395 (2020)
394 1137–1144. [https://doi.org/10.1016/S0140-6736\(20\)30607-3](https://doi.org/10.1016/S0140-6736(20)30607-3).
- 395 [2] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu,
396 J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R.
397 Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel
398 coronavirus in Wuhan, China, *The Lancet*. 395 (2020) 497–506.
399 [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 400 [3] R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented
401 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2), *Science*.
402 368 (2020) 489–493. <https://doi.org/10.1126/science.abb3221>.
- 403 [4] F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Pérez
404 Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li,
405 W.V. Kalina, D. Cooper, R.W. Frenck, L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal,

- 406 D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, W.C. Gruber, Safety and
407 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, *N. Engl. J. Med.* 383 (2020) 2603–2615.
408 <https://doi.org/10.1056/NEJMoa2034577>.
- [5] A.T. Widge, N.G. Roupael, L.A. Jackson, E.J. Anderson, P.C. Roberts, M. Makhene, J.D.
410 Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A.
411 Doria-Rose, S. O’Dell, S.D. Schmidt, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J.
412 Albert, K. Cross, V.-V. Edara, K. Floyd, M.S. Suthar, W. Buchanan, C.J. Luke, J.E.
413 Ledgerwood, J.R. Mascola, B.S. Graham, J.H. Beigel, Durability of Responses after SARS-
414 CoV-2 mRNA-1273 Vaccination, *N Engl J Med.* (2020) 4.
- [6] D.F. Robbiani, C. Gaebler, F. Muecksch, J.C.C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C.O.
416 Barnes, A. Gazumyan, S. Finkin, T. Hagglof, T.Y. Oliveira, C. Viant, A. Hurley, H.-H.
417 Hoffmann, K.G. Millard, R.G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S.T. Chen, V. Ramos,
418 R. Patel, J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweger, L. Nogueira, M. Pack, J.
419 Horowitz, F. Schmidt, Y. Weisblum, E. Michailidis, A.W. Ashbrook, E. Waltari, J.E. Pak, K.E.
420 Huey-Tubman, N. Koranda, P.R. Hoffman, A.P. West, C.M. Rice, T. Hatziioannou, P.J.
421 Bjorkman, P.D. Bieniasz, M. Caskey, M.C. Nussenzweig, Convergent Antibody Responses to
422 SARS-CoV-2 Infection in Convalescent Individuals, *Immunology*, 2020.
423 <https://doi.org/10.1101/2020.05.13.092619>.
- [7] J.A. Juno, H.-X. Tan, W.S. Lee, A. Reynaldi, H.G. Kelly, K. Wragg, R. Esterbauer, H.E. Kent, C.J.
425 Batten, F.L. Mordant, N.A. Gherardin, P. Pymm, M.H. Dietrich, N.E. Scott, W.-H. Tham, D.I.
426 Godfrey, K. Subbarao, M.P. Davenport, S.J. Kent, A.K. Wheatley, Immunogenic profile of
427 SARS-CoV-2 spike in individuals recovered from COVID-19, *Infectious Diseases (except*
428 *HIV/AIDS)*, 2020. <https://doi.org/10.1101/2020.05.17.20104869>.
- [8] F. Wu, A. Wang, M. Liu, Q. Wang, J. Chen, S. Xia, Y. Ling, Y. Zhang, J. Xun, L. Lu, S. Jiang, H. Lu,
430 Y. Wen, J. Huang, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
431 patient cohort and their implications, *MedRxiv Prepr.* (2020) 20.
432 <https://doi.org/10.1101/2020.03.30.20047365>.
- [9] Z. Han, F. Battaglia, S.R. Terlecky, Discharged COVID-19 Patients Testing Positive Again for
434 SARS-CoV-2 RNA: A Minireview of Published Studies from China, *J. Med. Virol.* (2020)
435 *jmv.26250*. <https://doi.org/10.1002/jmv.26250>.
- [10] G. Ye, Z. Pan, Y. Pan, Q. Deng, L. Chen, J. Li, Y. Li, X. Wang, Clinical characteristics of severe
437 acute respiratory syndrome coronavirus 2 reactivation, *J. Infect.* 80 (2020) e14–e17.
438 <https://doi.org/10.1016/j.jinf.2020.03.001>.
- [11] V.T. Hoang, T.L. Dao, P. Gautret, Recurrence of positive SARS-CoV-2 in patients recovered
439 from COVID-19, *J. Med. Virol.* (2020) *jmv.26056*. <https://doi.org/10.1002/jmv.26056>.
- [12] Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y. Yuen, Q.
442 Wang, H. Zhou, J. Yan, J. Qi, Structural and Functional Basis of SARS-CoV-2 Entry by Using
443 Human ACE2, *Cell.* (2020) S009286742030338X.
444 <https://doi.org/10.1016/j.cell.2020.03.045>.
- [13] L. Premkumar, B. Segovia-Chumbez, R. Jadi, D.R. Martinez, R. Raut, A. Markmann, C.
446 Cornaby, L. Bartelt, S. Weiss, Y. Park, C.E. Edwards, E. Weimer, E.M. Scherer, N. Roupael,
447 S. Edupuganti, D. Weiskopf, L.V. Tse, Y.J. Hou, D. Margolis, A. Sette, M.H. Collins, J. Schmitz,
448 R.S. Baric, A.M. de Silva, The receptor binding domain of the viral spike protein is an

- 449 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients, *Sci.*
450 *Immunol.* 5 (2020) eabc8413. <https://doi.org/10.1126/sciimmunol.abc8413>.
- 451 [14] C.W. Tan, W.N. Chia, X. Qin, P. Liu, M.I.-C. Chen, C. Tiu, Z. Hu, V.C.-W. Chen, B.E. Young,
452 W.R. Sia, Y.-J. Tan, R. Foo, Y. Yi, D.C. Lye, D.E. Anderson, L.-F. Wang, A SARS-CoV-2
453 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike
454 protein–protein interaction, *Nat. Biotechnol.* (2020). [https://doi.org/10.1038/s41587-020-](https://doi.org/10.1038/s41587-020-0631-z)
455 [0631-z](https://doi.org/10.1038/s41587-020-0631-z).
- 456 [15] Q.M. Hanson, K.M. Wilson, M. Shen, Z. Itkin, R.T. Eastman, P. Shinn, M.D. Hall, Targeting
457 ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug
458 repurposing screen of an AlphaLISA proximity assay, *Biochemistry*, 2020.
459 <https://doi.org/10.1101/2020.06.16.154708>.
- 460 [16] X. Xie, A. Muruato, K.G. Lokugamage, K. Narayanan, X. Zhang, J. Zou, J. Liu, C. Schindewolf,
461 N.E. Bopp, P.V. Aguilar, K.S. Plante, S.C. Weaver, S. Makino, J.W. LeDuc, V.D. Menachery,
462 P.-Y. Shi, An Infectious cDNA Clone of SARS-CoV-2, *Cell Host Microbe.* 27 (2020) 841-
463 848.e3. <https://doi.org/10.1016/j.chom.2020.04.004>.
- 464 [17] Davide Giavarina, Understanding Bland Altman analysis, *Biochem. Medica.* 25 (2015) 141–
465 151. <https://doi.org/10.11613/BM.2015.015>.
- 466 [18] N.Ö. Doğan, Bland-Altman analysis: A paradigm to understand correlation and agreement,
467 *Turk. J. Emerg. Med.* 18 (2018) 139–141. <https://doi.org/10.1016/j.tjem.2018.09.001>.
- 468 [19] N.A. Obuchowski, J.A. Bullen, Receiver operating characteristic (ROC) curves: review of
469 methods with applications in diagnostic medicine, *Phys Med Biol.* (2018) 29.
- 470 [20] C.T. Nakas, C.T. Yannoutsos, Ordered multiple-class ROC analysis with continuous
471 measurements, *Med. Stat.* 23 (November 30) 3437–49. <https://doi.org/10.1002/sim.1917>.
- 472 [21] P. Schober, C. Boer, L.A. Schwarte, Correlation Coefficients: Appropriate Use and
473 Interpretation, *Anesth. Analg.* 126 (2018) 1763–1768.
474 <https://doi.org/10.1213/ANE.0000000000002864>.
- 475 [22] J.D. Rights, S.K. Sterba, Quantifying explained variance in multilevel models: An integrative
476 framework for defining R-squared measures, *Psychol. Methods.* 24 (n.d.) 309–338.
477 <https://doi.org/10.1037/met0000184>.
- 478 [23] J.D. Rights, S.K. Sterba, A framework of R-squared measures for single-level and multilevel
479 regression mixture models, *Psychol. Methods.* 23 (n.d.) 434–457.
480 <https://doi.org/10.1037/met0000139>.
- 481 [24] J.D. Rights, S.K. Sterba, New Recommendations on the Use of R-Squared Differences in
482 Multilevel Model Comparisons, *Multivar. Behav. Res.* 55 (n.d.) 568–599.
- 483 [25] L.A. Jackson, E.J. Anderson, N.G. Roupahel, P.C. Roberts, M. Makhene, R.N. Coler, M.P.
484 McCullough, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A. McDermott, B.
485 Flach, N.A. Doria-Rose, K.S. Corbett, K.M. Morabito, S. O’Dell, S.D. Schmidt, P.A. Swanson,
486 M. Padilla, J.R. Mascola, K.M. Neuzil, H. Bennett, W. Sun, E. Peters, M. Makowski, J. Albert,
487 K. Cross, W. Buchanan, R. Pikaart-Tautges, J.E. Ledgerwood, B.S. Graham, J.H. Beigel, An
488 mRNA Vaccine against SARS-CoV-2 — Preliminary Report, *N. Engl. J. Med.* 383 (2020)
489 1920–1931. <https://doi.org/10.1056/NEJMoa2022483>.
- 490 [26] A. Lombardi, G. Bozzi, R. Ungaro, S. Villa, V. Castelli, D. Mangioni, A. Muscatello, A. Gori, A.
491 Bandera, Mini Review Immunological Consequences of Immunization With COVID-19

- 492 mRNA Vaccines: Preliminary Results, *Front. Immunol.* 12 (2021) 657711.
493 <https://doi.org/10.3389/fimmu.2021.657711>.
- [27] U. Sahin, A. Muik, E. Derhovanessian, I. Vogler, L.M. Kranz, M. Vormehr, A. Baum, K. Pascal, J. Quandt, D. Maurus, S. Brachtendorf, V. Lörks, J. Sikorski, R. Hilker, D. Becker, A.-K. Eller, J. Grützner, C. Boesler, C. Rosenbaum, M.-C. Kühnle, U. Luxemburger, A. Kemmer-Brück, D. Langer, M. Bexon, S. Bolte, K. Karikó, T. Palanche, B. Fischer, A. Schultz, P.-Y. Shi, C. Fontes-Garfias, J.L. Perez, K.A. Swanson, J. Loschko, I.L. Scully, M. Cutler, W. Kalina, C.A. Kyratsous, D. Cooper, P.R. Dormitzer, K.U. Jansen, Ö. Türeci, COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, *Nature*. 586 (2020) 594–599.
500 <https://doi.org/10.1038/s41586-020-2814-7>.
- [28] E.J. Anderson, N.G. Roupael, A.T. Widge, L.A. Jackson, P.C. Roberts, M. Makhene, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A. Doria-Rose, S. O’Dell, S.D. Schmidt, K.S. Corbett, P.A. Swanson, M. Padilla, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V.V. Edara, K. Floyd, M.S. Suthar, D.R. Martinez, R. Baric, W. Buchanan, C.J. Luke, V.K. Phadke, C.A. Rostad, J.E. Ledgerwood, B.S. Graham, J.H. Beigel, Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults, *N. Engl. J. Med.* 383 (2020) 2427–2438.
509 <https://doi.org/10.1056/NEJMoa2028436>.
- [29] N. Doria-Rose, M.S. Suthar, M. Makowski, S. O’Connell, A.B. McDermott, B. Flach, J.E. Ledgerwood, J.R. Mascola, B.S. Graham, B.C. Lin, S. O’Dell, S.D. Schmidt, A.T. Widge, V.-V. Edara, E.J. Anderson, L. Lai, K. Floyd, N.G. Roupael, V. Zarnitsyna, P.C. Roberts, M. Makhene, W. Buchanan, C.J. Luke, J.H. Beigel, L.A. Jackson, K.M. Neuzil, H. Bennett, B. Leav, J. Albert, P. Kunwar, Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19, *N. Engl. J. Med.* (2021) NEJMc2103916.
516 <https://doi.org/10.1056/NEJMc2103916>.
- [30] J.E. Ebinger, J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J.C. Prostko, E.C. Frias, J.L. Stewart, J.E. Van Eyk, J.G. Braun, S. Cheng, K. Sobhani, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2, *Nat. Med.* (2021).
520 <https://doi.org/10.1038/s41591-021-01325-6>.
- [31] X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y. Yang, Z. Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J. Xu, C. Yu, J. Li, Q. Zhou, W. Chen, A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2, *Science*. (2020) eabc6952.
525 <https://doi.org/10.1126/science.abc6952>.
- [32] L. Liu, P. Wang, M.S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J.F.-W. Chan, V. Sahi, A. Figueroa, X.V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P.D. Kwong, J.G. Sodroski, M.T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D.D. Ho, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike, *Nature*. 584 (2020) 450–456.
530 <https://doi.org/10.1038/s41586-020-2571-7>.
- [33] Y. Cai, J. Zhang, T. Xiao, H. Peng, S.M. Sterling, R.M. Walsh, S. Rawson, S. Rits-Volloch, B. Chen, Distinct conformational states of SARS-CoV-2 spike protein, *Science*. (2020) eabd4251. <https://doi.org/10.1126/science.abd4251>.
- 534
535

536

537

538

539